Benitec Biopharma Total Assets 2014-2022 | BNTC

Benitec Biopharma total assets from 2014 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Benitec Biopharma Annual Total Assets
(Millions of US $)
2021 $21
2020 $12
2019 $19
2018 $17
2017 $17
2016 $14
2015 $21
2014 $32
2013 $2
Benitec Biopharma Quarterly Total Assets
(Millions of US $)
2022-03-31 $10
2021-12-31 $14
2021-09-30 $18
2021-06-30 $21
2021-03-31 $13
2020-12-31 $16
2020-09-30 $9
2020-06-30 $12
2020-03-31 $0
2019-09-30 $0
2017-09-30 $16
2016-09-30 $16
2016-06-30 $14
2016-03-31 $20
2015-12-31 $20
2015-06-30 $21
2014-12-31 $26
2014-06-30 $32
2013-06-30 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.010B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.111B 10.23
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.588B 16.71
Biohaven Pharmaceutical Holding (BHVN) United States $10.141B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.081B 0.00
Arcus Biosciences (RCUS) United States $1.832B 46.46
Emergent Biosolutions (EBS) United States $1.646B 7.05
Myovant Sciences (MYOV) United Kingdom $1.264B 0.00
Zymeworks (ZYME) Canada $0.364B 0.00
Gelesis Holdings (GLS) United States $0.116B 0.00
Ambrx Biopharma (AMAM) United States $0.111B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00